The central role of lipid abnormalities in the genesis of atherosclerosis has focused on cholesterol. Therapy has concentrated on lowering cholesterol levels, especially cholesterol associated with low-density lipoprotein (LDL) particles. The circulating high-density lipoprotein (HDL) cholesterol concentration, however, appears to be a strong modifier of LDL cholesterol-associated risk for coronary artery disease. This article reviews the current state of our knowledge regarding HDL and explores the rational application of HDL measurements to patients with lipid abnormalities.
|Number of pages||11|
|State||Published - 1 Jan 1992|
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism